Passenger numbers up at Germany's Frankfurt Airport in April
Operator Fraport said the rise was fuelled by the Easter holiday, a period many Germans traditionally use for an early getaway.
The number of passengers was still only 85.2% of the levels seen in April 2019, before the coronavirus pandemic.
The highest number of travellers was recorded on April 11, with 198,000 passengers passing through Germany's biggest airport.
European traffic was particularly dynamic in April, with passenger growth of 6.8%.
Domestic flights to and from Frankfurt also saw a 3.3% increase in passengers compared to the same month last year.
The number of North America-bound travellers fell by 1.9% despite the Easter holidays.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a minute ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
3 minutes ago
- CBS News
More than 20% of NASA's workforce requests to leave agency
Nearly 4,000 employees, or more than 20% of NASA's workforce, have applied to leave the agency, NASA confirmed to CBS News Friday. About 3,870 employees have applied to depart NASA over two rounds through the Trump administration's deferred resignation program, NASA disclosed. The deadline for applications to the program is midnight Friday. With those deferred resignations, NASA's civil servant workforce would shrink from about 18,000 to 14,000 personnel. This figure also includes about 500 employees who were lost through normal attrition, the agency said. "Safety remains a top priority for our agency as we balance the need to become a more streamlined and more efficient organization and work to ensure we remain fully capable of pursuing a Golden Era of exploration and innovation, including to the Moon and Mars," NASA spokesperson Cheryl Warner said in a statement. According to NASA, about 870 employees applied to leave during the first round of the Deferred Resignation Program, and about 3,000 employees during the second round. The deferred resignation program was a buyout program introduced across the federal government by the White House's Department of Government Efficiency at the onset of the Trump administration in an effort to slash costs and reduce the size of the federal workforce. A White House budget proposal issued in May would see NASA's funding cut by about 25% for fiscal year 2026, from about $24 billion to $18 billion. NASA has also been roiled by a leadership crisis in recent months. In December, President Trump nominated billionaire private astronaut Jared Isaacman, a friend of former DOGE head Elon Musk, to serve as NASA's next administrator. Musk's SpaceX has several NASA contracts. However, in late May, Mr. Trump pulled Isaacman's nomination just ahead of the Senate confirmation vote, which was followed days later by a public fallout between Mr. Trump and Musk. Earlier this month, the president announced that Transportation Secretary Sean Duffy would temporarily lead the agency. Miles Doran contributed to this report.
